Tumor Therapeutic Vaccines
“Turning Antigens Innovation into Clinical Breakthroughs”
Our therapeutic cancer vaccines are designed to activate the immune system to specifically target and eliminate tumor cells. Leveraging our recombinant antigen platform, we develop high-quality antigens that form the foundation for next-generation cancer vaccines.
Product Overview
Therapeutic cancer vaccines work by delivering tumor-associated antigens to the immune system, enabling antigen-presenting cells to process and present them to T cells. This stimulates tumor-specific CTLs, enhances immune recognition of cancer cells, and generates long-lasting immunological memory to prevent recurrence.
Advantages
Comprehensive Antigen Expression Systems: Our recombinant antigen platform covers E. coli, yeast, insect cells, and HEK293, enabling recombinant expression of a wide variety of tumor-associated antigens.
Proprietary Insect Cell Line: Our SF-α is the first insect cell line approved by CFDA for human vaccine production in China, providing a unique and reliable foundation for tumor vaccine development.
High-Purity Antigen Production: Using the insect cell baculovirus expression system, we achieve over 95% purity in recombinant antigens such as prostate cancer antigen, ensuring safety and efficacy for therapeutic vaccines.
Validated Quality & Compliance: Our insect cell matrix for tumor vaccine production has passed the full inspection qualification report issued by the Chinese Academy of Sciences, demonstrating regulatory compliance and product reliability.
R&D Progress
Our pipeline currently focuses on three major vaccine products:
-
PAP/PSA-based vaccines for prostate cancer.
-
E6/E7-based vaccines for cervical cancer.
-
Neoantigen vaccines for a broad range of solid tumors.
These products integrate advanced antigen expression systems and optimized vaccine design to enhance immunogenicity and therapeutic efficacy.